Management of premature menopause
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
There has been some confusion among women and health professionals since the publication of the Women's Health Initiative and Million Women studies about the management of premature ovarian failure (POF). Both studies were undertaken in women aged 50 and over, and cannot be extrapolated to their younger counterparts, who would normally be producing their endogenous estrogen, since they have functioning ovaries. Estrogen-based replacement therapy is the main stay of treatment for women with POF and is recommended at least until the average age of natural menopause (52 years in the UK). This view is endorsed by regulatory bodies such as the Committee on Safety of Medicines (now the Commission on Human Medicines) in the UK. No evidence shows that estrogen replacement increases the risk of breast cancer to a level greater than that found in normally menstruating women, and women with POF do not need to start mammographic screening early unless other risk factors are present, such as family history.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GH therapy is approved for replacement in adults with rigorously proven GHD or for treating HIVrelated muscle wasting (164).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [164]
Citations
Cites
Livebirth after orthotopic transplantation of cryopreserved ovarian tissue
Donnez, J., Dolmans, M., Demylle, D., Jadoul, P., Pirard, C., Squifflet, J., Martinez-Madrid, B., & Van Langendonckt, A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17222-x · Cited by 1,631
Age at Menopause, Cause-Specific Mortality and Total Life Expectancy
Ossewaarde, M. E., Bots, M. L., Verbeek, A. L. M., Peeters, P. H. M., van der Graaf, Y., Grobbee, D. E., & van der Schouw, Y. T. (2005) · Epidemiology · doi:10.1097/01.ede.0000165392.35273.d4 · Cited by 443
Age at Natural Menopause and Risk of Cardiovascular Disease
Hu, F. B., Grodstein, F., Hennekens, C. H., Colditz, G. A., Johnson, M., Manson, J. E., Rosner, B., & Stampfer, M. J. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.10.1061 · Cited by 413
COMMITTEE ON SAFETY OF MEDICINES
SCOWEN, E. (1978) · British Journal of Anaesthesia · doi:10.1093/bja/50.12.1270-a · Cited by 296
Age at Natural Menopause and Total Mortality and Mortality from Ischemic Heart Disease
Jacobsen, B. K., Knutsen, S. F., & Fraser, G. E. (1999) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00170-x · Cited by 253
An update: spontaneous premature ovarian failure is not an early menopause
Nelson, L. M., Covington, S. N., & Rebar, R. W. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.11.059 · Cited by 230
Menstrual factors in relation to breast cancer risk.
Titus-Ernstoff, L. T., Longnecker, M. P., Newcomb, P. A., Dain, B., Greenberg, E. R., Mittendorf, R. L., Stampfer, M. J., & Willett, W. C. (1998) · PubMed · Cited by 165
Arlt, W. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02062 · Cited by 131
Present and Future Options for the Preservation of Fertility in Female Adolescents with Cancer
Beerendonk, C. C. M., & Braat, D. D. M. (2005) · KARGER eBooks · doi:10.1159/000084101 · Cited by 34
Cited by
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Premature menopause or early menopause: Long-term health consequences
Shuster, L. T., Rhodes, D. J., Gostout, B. S., Grossardt, B. R., & Rocca, W. A. (2010) · Maturitas · doi:10.1016/j.maturitas.2009.08.003 · Cited by 808
Long-term health consequences of premature or early menopause and considerations for management
Faubion, S. S., Kuhle, C. L., Shuster, L. T., & Rocca, W. A. (2015) · Climacteric · doi:10.3109/13697137.2015.1020484 · Cited by 544
Langrish, J. P., Mills, N. L., Bath, L. E., Warner, P., Webb, D. J., Kelnar, C. J., Critchley, H. O. D., Newby, D. E., & Wallace, W. H. B. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.126516 · Cited by 207
Cartwright, B., Robinson, J., Seed, P. T., Fogelman, I., & Rymer, J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4063 · Cited by 156
“It is recommended that women with POF take estrogen treatment until at least the average age of menopause (51 to 52) to prevent bone loss, reduce cardiovascular risk and alleviate symptoms (1, 22).”
BackgroundMethodInfluential
Metadata
- Authors
- Writing Group for the British Menopause Society Council
- Corresponding author
- Writing Group for the British Menopause Society Council
- Venue
- Menopause International
- Publisher
- Informa UK Limited
- Published
- 2007-03-01
- Volume
- 13
- Issue
- 1
- Pages
- 44-45
- ISSN
- 1754-0453 (ISSN-L)
- OpenAlex
- W2404770992
- Semantic Scholar
- 453d9951c5b5e0c8cc868b0f92e4b7e90505cb45
- Cited by
- 45
- References
- 9
- Citations by year
- 2025: 1 · 2024: 3 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 4 · 2016: 5 · 2015: 3 · 2014: 4 · 2013: 1 · 2012: 5
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Menopause international (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Keywords
- premature menopause, premature ovarian failure, estrogen replacement therapy, hormone replacement therapy, Women's Health Initiative, Million Women Study, breast cancer risk, mammography screening, ovarian function, endogenous estrogen
- MeSH terms
- Female, Humans, Menopause, Premature, Estrogen Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.